Soteropoulos Paula 4

What Happened

• Paula Soteropoulos, a director of Dianthus Therapeutics (DNTH), exercised options and sold the resulting 599 shares on March 31, 2026. She exercised the options at $8.44 per share (cost $5,056) and immediately sold the 599 shares in the open market at $80.11 each for total proceeds of $47,986 — a pre-tax gross difference of about $42,930. The filing shows the related derivative security was removed on exercise.

Key Details

• Date: 2026-03-31
• Option exercise: 599 shares acquired at $8.44 each, total cost $5,056 (transaction code M)
• Open-market sale: 599 shares sold at $80.11 each, proceeds $47,986 (transaction code S)
• Derivative removal: 599 derivative units reported disposed at $0.00 (reflects conversion/removal of the option)
• Shares owned after the transaction: not specified in the provided filing
• Footnotes: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted Dec 23, 2025 (F1). Vesting schedule of the underlying award noted (25% vested Apr 6, 2023; remainder vests monthly over three years) (F2)
• Timeliness: Filing dated 2026-04-01 for a 2026-03-31 transaction — appears timely (Form 4 required within two business days)

Context

• This was an exercise-and-sale on the same day (common "exercise and sell" or cashless-style transaction), which converts vested options into shares and then sells them. The presence of a 10b5-1 plan indicates the sale was prearranged and therefore more likely routine rather than a discretionary trade.